Open AccessFeasibility of pharmacometabolomics to identify potential predictors of paclitaxel pharmacokinetic variability
Author(s) -
Li Chen,
Ciao-Sin Chen,
Yihan Sun,
Norah Lynn Henry,
Kathleen A. Stringer,
Daniel L Hertz
Publication year - 2021
Publication title -
cancer chemotherapy and pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.112
H-Index - 111
eISSN - 1432-0843
pISSN - 0344-5704
DOI - 10.1007/s00280-021-04300-7
Subject(s) - paclitaxel , pharmacokinetics , medicine , oncology , pharmacology , chemotherapy
Paclitaxel is a commonly used chemotherapy drug with substantial variability in pharmacokinetics (PK) that affects treatment efficacy and toxicity. Pharmacometabolomic signatures that explain PK variability could be used to individualize dosing to improve therapeutic outcomes. The objective of this study was to identify pretreatment metabolites or metabolomic signatures that explain variability in paclitaxel PK.